Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol. 2002;10(2):81–9.

Article  PubMed  Google Scholar 

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. In: Seminars in diagnostic pathology. WB Saunders; 2006. vol. 23, no. 2, p. 70–3.

Demetri GD, Von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl_2):S-1.

Article  CAS  Google Scholar 

Hatipoğlu E. Extragastrointestinal stromal tumor (EGIST): a 16-year experience of 13 cases diagnosed at a single center. Med Sci Monit. 2018;19(24):3301–6.

Article  Google Scholar 

Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caterino S, Lorenzon L, Petrucciani N, Iannicelli E, Pilozzi E, Romiti A, et al. Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. World J Surg Oncol. 2011;1(9):13.

Article  Google Scholar 

Patnaik S, Jyotsnarani Y, Rammurti S. Radiological features of metastatic gastrointestinal stromal tumors. J Clin Imaging Sci. 2012;28(2):43.

Article  Google Scholar 

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.

Article  CAS  PubMed  Google Scholar 

Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 2002;160(5):1567–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fletcher JA, Fletcher CDM, Rubin BP, Ashman LK, Corless CL, Heinrich MC. KIT gene mutations in gastrointestinal stromal tumors. Am J Pathol. 2002;161(2):737–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466–78.

Article  CAS  PubMed  Google Scholar 

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.

Article  CAS  PubMed  Google Scholar 

Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28(7):889–94.

Article  PubMed  Google Scholar 

Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CDM, et al. Correlation of kinase genotype and clinical outcome in the north american intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group. J Clin Oncol. 2008;26(33):5360–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors. JAMA Oncol. 2016;2(7):922–8.

Article  PubMed  PubMed Central  Google Scholar 

Mandelker D, Marra A, Mehta N, Selenica P, Yelskaya Z, Yang C, et al. Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations. npj Precis Onc. 2023;7(1):1–6.

Article  CAS  Google Scholar 

Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol. 2016;17(5):632–41.

Article  CAS  PubMed  Google Scholar 

Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, et al. Key issues in the clinical management of gastrointestinal stromal tumors: an expert discussion. Oncologist. 2015;20(7):823.

Article  PubMed  PubMed Central  Google Scholar 

Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, et al. BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013;4(2):310.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575(7781):229–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Urbini M, Astolfi A, Indio V, Nannini M, Schipani A, Bacalini MG, et al. Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFRA/SDH/RAS-P WT GIST. Sci Rep. 2020;10(1):19829.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Urbini M, Indio V, Tarantino G, Ravegnini G, Angelini S, Nannini M, et al. Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST. Genes Chromosomes Cancer. 2019;58(9):636–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012;13(3):265–74.

Article  PubMed  Google Scholar 

Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006Apr;30(4):477–89.

Article  PubMed  Google Scholar 

Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 2000;88(1):66–74.

Article  CAS  PubMed  Google Scholar 

DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PWT, Demetri GD, et al. Placebo-controlled randomized trial of adjuvant imatinib mesylate following the resection of localized, primary gastrointestinal stromal tumor (GIST). Lancet. 2009;373(9669):1097–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casali PG, Cesne AL, Velasco AP, Kotasek D, Rutkowski P, Hohenberger P, et al. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆. Ann Oncol. 2021;32(4):533–41.

Article  CAS  PubMed  Google Scholar 

Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, et al. Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-Year follow-up. JAMA Oncol. 2020;6(8):1241–6.

Article  PubMed  Google Scholar 

Blay JY, Schiffler C, Bouché O, Brahmi M, Duffaud F, Toulmonde M, Landi B, Lahlou W, Pannier D, Bompas E, Bertucci F. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Ann Oncol. 2024;35(12):1157–68.

Article  CAS  PubMed  Google Scholar 

Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4(12):e184060.

Article  PubMed  PubMed Central